Regenxbio (RGNX) Accumulated Expenses (2014 - 2025)

Regenxbio's Accumulated Expenses history runs 12 years deep, the most recent figure standing at $17.4 million for Q4 2025.

• In Q4 2025, Accumulated Expenses fell 1.07% year-over-year to $17.4 million; the TTM figure through Dec 2025 stood at $17.4 million (down 1.07% YoY), while the FY2025 annual figure was $17.4 million, down 1.07% from the prior year.
• Accumulated Expenses was $17.4 million for Q4 2025 at Regenxbio, up from $15.1 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $50.5 million in Q2 2023 to a low of $8.1 million in Q1 2024.
• Historically, Accumulated Expenses has averaged $31.3 million across 5 years, with a median of $38.6 million in 2021.
• The sharpest annual moves came in 2021 and 2023: Accumulated Expenses soared 521.34% in 2021, then slumped 82.08% in 2023.
• A 5-year view of Accumulated Expenses shows it stood at $19.8 million in 2021, then jumped by 135.75% to $46.8 million in 2022, then rose by 6.22% to $49.7 million in 2023, then plunged by 64.58% to $17.6 million in 2024, then retreated by 1.07% to $17.4 million in 2025.
• The last three Accumulated Expenses figures came in at $17.4 million (Q4 2025), $15.1 million (Q3 2025), and $35.6 million (Q2 2025), per Business Quant data.